SEC. 2. COVERED PRODUCT DEVELOPMENT AND PROCURE-
MENT. 
(a) ENHANCING
DEVELOPMENT, PROCUREMENT, 
AND MANUFACTURING CAPACITY.— 
(1) IN GENERAL.—The Secretary of Health and 
Human Services shall, as appropriate, award con-
tracts, grants, and cooperative agreements, and 
enter into other transactions— 
(A) expanding and enhancing covered 
product research and development; 
(B) procuring covered products; and 
(C) expanding and enhancing capacity for 
manufacturing covered products. 
(2) AUTHORIZATION OF APPROPRIATIONS.—To 
carry out this subsection, there is authorized to be 
appropriated $20,000,000,000 for fiscal years 2021 
through 2025, to remain available until expended. 
(b) REPORT ON VACCINE AND THERAPEUTIC MANU-
FACTURING AND ADMINISTRATION CAPACITY.—Not later 
than December 31, 2021, the Secretary shall submit to 
the Committee on Energy and Commerce of the House 
of Representatives and the Committee on Health, Edu-
cation, Labor and Pensions of the Senate a report detail-
ing— 
(1) an assessment of the estimated supply of 
covered products necessary to prevent and control 
VerDate Sep 11 2014 
23:02 Feb 07, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H349.IH
H349
pbinns on DSKJLVW7X2PROD with BILLS
the spread of SARS–CoV–2 and COVID–19, domes-
tically and internationally; 
(2) an assessment of current and future domes-
tic manufacturing capacity for covered products, in-
cluding identification of any gaps in manufacturing 
capacity, including— 
(A) identification of any gaps in capacity 
for manufacturing; and 
(B) an analysis of the effects of shifting 
manufacturing resources to address COVID–19; 
(3) activities conducted to expand and enhance 
manufacturing capacity for covered products to lev-
els sufficient to prevent and control the spread of 
SARS–CoV–2 and COVID–19, domestically and 
internationally, including a list and explanation of 
all contracts, grants, and cooperative agreements 
awarded, and other transactions entered into, for 
purposes of such expansion and enhancement and 
how such activities will help to meet future domestic 
manufacturing capacity needs; 
(4) a plan for the ongoing support of enhanced 
manufacturing capacity for covered products, domes-
tically and internationally; and 
(5) a plan— 
VerDate Sep 11 2014 
23:02 Feb 07, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H349.IH
H349
pbinns on DSKJLVW7X2PROD with BILLS
(A) to ensure that manufacturing capacity 
meets the distribution targets and goals of cov-
ered products, domestically and internationally; 
and 
(B) to support the administration of cov-
ered products approved or authorized by the 
Food and Drug Administration to prevent and 
control the spread of SARS–CoV–2 and 
COVID–19, domestically and internationally, 
including Federal workforce enhancements nec-
essary to administer such products. 
(c) DEFINITIONS.—In this section: 
(1) The term ‘‘ancillary medical supply’’ in-
cludes— 
(A) vials; 
(B) bandages; 
(C) alcohol swabs; 
(D) syringes; 
(E) needles; 
(F) gloves and other personal protective 
equipment; and 
(G) other medical products the Secretary 
determines necessary for the administration of 
covered products. 
VerDate Sep 11 2014 
23:02 Feb 07, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H349.IH
H349
pbinns on DSKJLVW7X2PROD with BILLS
(2) The term ‘‘covered product’’ means a vac-
cine, therapeutic, or ancillary medical supply to pre-
vent and control the spread of SARS–CoV–2 and 
COVID–19. 
(3) The term ‘‘Secretary’’ means the Secretary 
of Health and Human Services. 
Æ 
VerDate Sep 11 2014 
23:02 Feb 07, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H349.IH
H349
pbinns on DSKJLVW7X2PROD with BILLS